PNC Financial Services Group
PTGX icon

PNC Financial Services Group’s Protagonist Therapeutics PTGX Stock Holding History

PNC Financial Services Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546K Buy
4,458
+460
+12% +$48K ﹤0.01% 1727
2026
Q1 		$421K Buy
3,998
+1,039
+35% +$92K ﹤0.01% 1798
2025
Q4 		$258K Buy
2,959
+221
+8% +$18.1K ﹤0.01% 2114
2025
Q3 		$182K Buy
2,738
+324
+13% +$18.4K ﹤0.01% 2368
2025
Q2 		$133K Buy
2,414
+422
+21% +$20.3K ﹤0.01% 2505
2025
Q1 		$96.3K Buy
1,992
+551
+38% +$23.1K ﹤0.01% 2688
2024
Q4 		$55.6K Sell
1,441
-288
-17% -$12.6K ﹤0.01% 3042
2024
Q3 		$77.8K Buy
1,729
+1,715
+12,250% +$69.3K ﹤0.01% 2824
2024
Q2 		$485 Buy
+14
New +$410 ﹤0.01% 4540
2024
Q1 		– Sell
-5
Closed -$115 – 4792
2023
Q4 		$115 Sell
5
-110
-96% -$1.93K ﹤0.01% 4513
2023
Q3 		$1.92K Hold
115
– – ﹤0.01% 4255
2023
Q2 		$3.18K Hold
115
– – ﹤0.01% 4236
2023
Q1 		$2.65K Buy
+115
New +$1.93K ﹤0.01% 4236

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PNC Financial Services Group's PTGX Position: Q2 2026 in Review

PNC Financial Services Group increased its Protagonist Therapeutics (PTGX) stake by 12% in Q2 2026, buying an estimated $48K and bringing the position to 4,458 shares worth $546K. The position accounts for ﹤0.01% of the portfolio, ranked #1727.

PNC Financial Services Group first reported a position in PTGX in Q1 2023 and has held it in 13 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • PNC Financial Services Group held 4,458 shares of Protagonist Therapeutics worth $546K as of Q2 2026.
  • PNC Financial Services Group bought 460 Protagonist Therapeutics shares in Q2 2026, an estimated $48K.
  • Protagonist Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #1727 holding.
  • PNC Financial Services Group first reported a position in Protagonist Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.